A $75 Million Drug Sale Lands Teva a $235 Million Penalty
- Teva infringed Glaxo patent on Coreg, appeals court says
- Teva’s generic sales added up to three times as much pain
Photographer: Chris Ratcliffe/Bloomberg
This article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
Teva Pharmaceutical Industries Ltd.’s sale of $74.5 million of a generic heart treatment resulted in a court ruling ordering it to pay a penalty three times that amount to reimburse GlaxoSmithKline Plc.